In this presentation, Saar Gill, MD, examines the lessons learned from a decade of CAR-T therapy for CLL, B-cell lymphoma and ALL, and reviews clinical reports from ASH 2016 relevant to the mechanisms of CART and potential concerns. In his analysis of ASH 2016, Dr. Gill focuses on studies at Penn in ALL (CAR-T-22), CLL (CAR-T+ibrutinib) and myeloma. He closes with an evaluation of novel strategies to prevent relapse and optimal manufacturing strategies.